Related references
Note: Only part of the references are listed.Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Tim Illidge et al.
LEUKEMIA & LYMPHOMA (2015)
Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma
Robert Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma
Sylvain Garciaz et al.
HEMATOLOGICAL ONCOLOGY (2014)
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
Jason A. Dubovsky et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
Adrian Wiestner
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2012)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Share Paper
